Evolus, Inc. (EOLS)
Market Cap | 766.22M |
Revenue (ttm) | 266.27M |
Net Income (ttm) | -50.42M |
Shares Out | 63.59M |
EPS (ttm) | -0.81 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 733,234 |
Open | 12.33 |
Previous Close | 12.24 |
Day's Range | 11.64 - 12.33 |
52-Week Range | 9.25 - 17.82 |
Beta | 1.28 |
Analysts | Strong Buy |
Price Target | 24.67 (+104.73%) |
Earnings Date | Mar 4, 2025 |
About EOLS
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California. [Read more]
Financial Performance
In 2024, Evolus's revenue was $266.27 million, an increase of 31.76% compared to the previous year's $202.09 million. Losses were -$50.42 million, -18.26% less than in 2023.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for EOLS stock is "Strong Buy." The 12-month stock price forecast is $24.67, which is an increase of 104.73% from the latest price.
News

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team w...

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of 29,763...

Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript
Evolus, Inc. (NASDAQ:EOLS) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Nareg Sagherian - VP and Head of Global IR and Corporate Communications David Moatazedi - Pre...

Evolus posts quarterly profit on strong sales of cosmetic injection
Cosmetic drugmaker Evolus reported a fourth-quarter profit versus a year-ago loss on Tuesday, on strong demand for its wrinkle treatment Jeuveau which competes with Botox.

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced its financial results for the fourth ...

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team w...

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team w...

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will repor...

US FDA approves Evolus' anti-wrinkle gels
Evolus said on Thursday the U.S. Food and Drug Administration has approved its two new anti-wrinkle injectable gels, expanding the company's product portfolio beyond its cosmetic injection Jeuveau.

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that the U.S. Food and Drug Administr...

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced its preliminary, unaudited net...

Evolus: Still Bullish, But Business Faces Tricky Challenges In '25
I previously rated Evolus, Inc. stock a “Buy” due to its litigation settlement with AbbVie, strong revenue targets, and promising product performance. Despite positive updates, Evolus stock fell sharp...

Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript
Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript

Evolus Reports Third Quarter 2024 Results
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results f...

Evolus to Participate in Stifel 2024 Healthcare Conference
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team w...

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the EU Medical Dev...

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it recently surpas...

Evolus to Report Third Quarter Financial Results on November 6, 2024
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will repor...

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the company will be ringing the Nasda...

Evolus, Inc. (EOLS) Q2 2024 Earnings Call Transcript
Evolus, Inc. (NASDAQ:EOLS) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Nareg Sagherian - Vice President and Head of Global Investor Relations and Corporate Communic...

Evolus reports first-ever adjusted profit in Q2 fueled by strong sales of Botox rival
Evolus , an anti-wrinkle injection maker, reported its first-ever quarterly profit on an adjusted basis on Wednesday, driven by strong sales of its Botox rival Jeuveau.

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results f...

Evolus to Hold Investor Day on September 12, 2024
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will host ...

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio, has commenced operations in Australia with the launch of N...

Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Sandra Beaver...